Trial Profile

A Clinical Study of the Safety, Efficacy, and Cell Pharmacokinetics of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 08 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; RD06 05 (Primary)
Indications Anti-glomerular basement membrane disease; Anti-neutrophil cytoplasmic antibody-associated vasculitis; Autoimmune disorders; Glomerulonephritis; Granulomatosis with polyangiitis; Lupus nephritis; Membranous glomerulonephritis; Microscopic polyangiitis; Myositis; Systemic lupus erythematosus; Systemic scleroderma
Focus Adverse reactions
Sponsors Nanjing Bioheng Biotech

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com